Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that the Company has elected to exercise its acceleration right under the warrant indenture (the “Indenture”) governing the common share purchase warrants of the Company (the “NovemberWarrants”) issued on November 1, 2019, Pursuant to the terms of the Indenture, the Company may accelerate the expiry date of the November Warrants when the daily volume-weighted average trading price (the “VWAP”) of the common shares of the Company (the “Common Shares”) exceeds $0.35 for the preceding 20 consecutive trading days on the Canadian Securities Exchange (the “CSE”).